Central Drug Research Institute, Lucknow

Ranjana Srivastava +91-9335-819-609 [email protected]

Former Head – Microbiology Division Central Drug Research Institute, Lucknow

An astute professional with 38 years of rich & qualitative experience in scientific domain. A blend of successful science & people management – which includes building the vision of the department, people management & future projection, appraisals of development of people within team and department. Over the years, have participated in national & international committees, meetings & conferences, publications in journals; with an aspiration to contribute to the overall scientific development and growth.

Core Strengths * Microbiology * Biotechnology * Molecular Biology

Professional Background

 Scientist G (till 2011) with Central Drug Research Institute, India

 Post Doctorate Research Associate with Brown University, Providence, USA from 1978-82

 University of Brussels, Belgium from 1972-74

Deputation abroad

 DBT Overseas Research Associate-ship with Center for Vaccine Development, Baltimore, USA In 1988

 Visiting Scientist (Indo – US VAP) with Center for Vaccine Development, Baltimore, USA in 1990, 1991, 1992 & 1993

 Visiting Scientist (Indo – French) with Institute Pasteur de Lille, Lille, France in 2002 & 2004

Areas of research

 Genetics of E. coli RNA Polymerase  Pathogenesis of Vibrio cholerae  Molecular basis for band and interband pattern in polytene chromosomes of fungus fly Sciara coprophila  Cellulose degradation  Tuberculosis Significant Milestones

Development of a DNA diagnostic probe for Tuberculosis

By molecular cloning and DNA hybridization, a repetitive sequence specific to Mycobacterium tuberculosis was selected which was developed as diagnostic probe to detect tubercle bacilli in clinical fluids. The probe was sequenced to establish the novelty, uniqueness and specificity was established with thousands of clinical isolates of M. tuberculosis and clinical specimens and patent in India, Europe and USA was obtained. PCR based diagnostic assay detects M.tuberculosis DNA which has been brought to Real Time PCR platform with Taqman technology. It has been commercialized as “MycoView MTB PCR detection kit” by Central Drug Research Institute (CDRI).

Development of surrogate screens for high throughput screening of anti-TB compounds

User friendly nonhazardous rapid screens have been developed to preselect active anti-TB compounds using apathogenic, non hazardous M. bovis BCG and M. aurum as surrogate strains and GFP and firefly luciferase as reporters. Use of these reporter strains allow to select an active compound within 48 h which were further validated in isolation on recombinant M.tuberculosis expressing GFP or luciferase. M. aurum as surrogate strain of M. tuberculosis for screening FasII inhibitors developed using protein- protein interaction and bacterial two hybrid system.

Mining new drug targets from TB genome by genetic approaches

Branched chain amino acids (BCAA; isoleucine, leucine and valine; ILV) biosynthesis pathway was explored for novel targets for the development of new anti TB drugs as BCAA auxotrophs of mycobacteria fail to grow in the host. Another approach used in vivo expression technology (IVET) and in vivo induced antigen technology (IVIAT) for selection of genes expressed during infection of M. tuberculosis in macrophages, mice and human. A novel vector was developed with a bicistronic reporter for cloning of functional promoters during infection in macrophages and in mice. The bicistronic reporter is a transcriptional fusion of promoterless green fluorescent protein and kanamycin resistance genes. The selection strategy lies in selection of fluorescent kanamycin resistant clones surviving in the macrophages/ lungs after giving kanamycin assault to macrophage/ mice. One of the gene identified by IVIAT, Rv3303c has been characterized as virulence factor which protects TB bacilli against oxidative stress and is upregulated during infection ex vivo and in vivo.

New chemical entities

A number of synthetic lead anti-TB compounds were identified which are classified as (i) glycosylated propanamides (b) glycosylated and substituted ureas and thioureas (c) diglycoxylated diaminoalcohol (d) substituted amino glycosidated popanoates (e) phenyl cyclopropyl methanomes (f) thiazidine thiones (g) galactopyranosylated amino alcohols (h) daryloxy methane phenanthrenes (i) ICL /arylalkyl dideoxy glucopyranisides . IPR has been secured and published .

Development of in vivo murine infection model for M. fortuitum

A murine infection model for M. fortuitum was developed which displays active and chronic infection. The infection produce characteristic visible disease symptoms which disappeared during chronic infection. Administration of drug resulted in loss of symptoms in infected mice thus making it a rapid in vivo screening model and was used to screen compounds active against NTM infection.

Scholastics & Awards

Ph.D. students guided 17 MD Thesis 6

Awards

Shakuntala Amirchand Prize of ICMR 1986 CSIR New Idea Fund 2005

Publications 1. R. Srivastava, C. Toussaint and J.P. Lecocq 1974. A rifampicin resistant mutation of E. coli whose phenotypic expression is dependent on the composition of the medium and recA allele. Mutation Res. 23, 25. 2. R. Srivastava, V.B. Sinha, B.S. Srivastava. 1979. Re-evaluation of antibacterial and anti-toxin immunities in experimental cholera. Ind. J. Med. Res. 70, 369. 3. B.S. Srivastava, V.B. Sinha, R. Srivastava. 1979. Attenuated recombinant strains of Vibrio cholerae for oral immunization. Bull. Wld. Hlth. Org. 57, 649. 4. R. Srivastava, V.B. Sinha, B.S. Srivastava. 1980. Events in the pathogenesis of experimental cholera: role of bacterial adherence and multiplication. J. Med. Microbiol. 13, 1. 5. R. Srivastava, B.S. Srivastava. 1980. Isolation of a non-adhesive mutant of Vibrio cholerae and chromosomal localization of the gene controlling mannose sensitive adherence to intestinal mucosa. J. Gen. Microbiol. 117, 275. 6. A.A. Khan, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1985. Regulation of toxin biosynthesis by plasmids in vibrio cholerae. J. Gen. Microbiol. 131, 2653. 7. R. Srivastava, A.A. Khan, B.S. Srivastava. 1985. Immunological detection of cloned antigenic genes of Vibrio cholerae in Escherichia coli. Gene, 40, 267. 8. R. Srivastava, V.B. Sinha, B.S. Srivastava 1989 . Chromosomal; transfer and in vivo cloning of genes in Vibrio cholerae using RP4::mini-Mu. Gene 75, 253. 9. A.W. Kerrebroeck, R. Srivastava, S.A. Gerbi. 1989. Isolation and characterization of ribosomal DNA variants from Sciara coprophila. J. Mol. Biol. 210, 1. 10. J.R. Czezulin, R. Srivastava, B.S. Srivastava, J.B. Kaper. 1990. Characterization of a possible colonizing factor of Vibrio cholerae. 01. Proc. Amer. Soc. Microbiol. 108. 11. R. Srivastava, R. Bharti, A.K. Srivastava. 1990. Characterization of a novel cellobiase from Bacillus subtilis and expression of its structural gene in Escherichia coli. Biotech. Lett. 12, 541. 12. R. Srivastava, S. S. Ali, B. S. Srivastava. 1991. Cloning of xylanase gene of Streptomyces flavogriseus in Escherichia coli and bacteriophage lambda induced lysis for the release of cloned enzyme. FEMS Microbiol Lett. 78, 201. 13. C.K.M. Tripathi, S.S. Ali, R. Srivastava. 1992. Characterization of xylanase activity of Streptomyces wedmorensis. Ind. J. Exptl. Biol. 30, 741. 14.A. Jacob, R. Srivastava, V.B. Sinha, M.K. Sahib, J.B. Kaper, B.S. Srivastava. 1993. Identification of a 33 kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae el tor and its role in protection. Vaccine, 11, 376. 15. V.B. Sinha, A. Jacob, R. Srivastava ,J.B. Kaper, B.S. Srivastava. 1993. Identification of the flagellar antigens of Vibrio cholerae el tor and their role in protection. Vaccine, 11, 372A. 16.R. Srivastava, A.K. Srivastava. 1993. Characteriozation of a bacterial xylanase resistant to repression by glucose and xylose. Biotech. Lett. 15, 847. 17. K. Krishna Kumar, R, Srivastava, V.B. Sinha, J. Mechalski, J.B. Kaper, B.S.Srivastava. 1994. recA mutations reduce adherence and colonization of classical and el tor strains of Vibrio cholerae. Microbiology 140, 1217. 18.S.N. Singh, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1994. A 53 kDa protein of Vibrio cholerae classical strain 0395 involved in intestinal colonization. Microbial Pathogenesis 17, 69. 19. R. Srivastava, G. Prasanna Kumar, K.K. Srivastava. 1995. Genetic construction of a cellulolytic Escherichia coli. Gene 164, 185. 20.D. Kumar, B.S. Srivastava, N. B. Singh, R. Srivastava. 1996. Identification of a 25 kDa protein of Mycobacterium bovis BCG to distinguish BCG from Mycobacterium tuberculosis. J. Clin. Microbiol. 34, 224. 21.R. Srivastava, D. Kumar, P Subramaniam, B.S. Srivastava. 1997. - galactosidase reporter system in mycobacteria and its application in rapid antimycobacterial drug screening. Biochem. Biophys. Res. Commun. 235, 602. 22.R. Srivastava, D. Kumar, B. S. Srivastava.1997. Recombinant Mycobacterium aurum expressing Escherichia coli -galactosidase in high through put screening of antituberculosis drugs. Biochem. Biophys. Res. Commun. 240, 536. 23.V.P. Bondre, R. Srivastava, V.B. Sinha, B.S. Srivastava. 1997. Screening of TnphoA mutants of Vibrio cholerae 0139 for identification of antigens involved in colonization. J. Med. Microbiol. 46, 1007. 24.A.Shukla, M.P. Dubey, R.Srivastava, B.S. Srivastava .1998. Differential expression of proteins during healing of cutaneous wounds in experimental and normal and chronic models. Biochem. Biophys. Res. Commun. 244, 434. 25.D. Kumar, B.S. Srivastava, R. Srivastava. 1998. Genetic rearrange-ments leading to disruption of heterologous gene expression in mycobacteria: An observation with -galactosidase in Mycobacterium smegmatis. Vaccine, 16, 1212. 26.R. Srivastava, D.K. Deb, K.K. Srivastava, C. Locht, B. S. Srivastava. 1998. Green fluorescent protein as a reporter in rapid screening of antituberculosis compounds in vitro and in macrophages. Biochem. Biophys. Res. Commun.. 253, 431. 27.R. Srivastava, B.S. Srivastava. 2000. Tuberculosis vaccines. IDrugs, 3, 408. 28.D.K.Deb, K.K.Srivastava, R. Srivastava, B.S. Srivastava. 2000. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem. Biophys. Res. Comm. 279, 457. 29.R. Srivastava, B.S.Srivastava. 2000. Tuberculosis vaccines: a critical role for T-cells. Curr. Opinion Anti-inflammatory & Immunomodulatory Investigational Drugs 2 (2), 100. 30.M. Waskar, D. Kumar, A. Kumar, R. Srivastava. 2000. Ioslation of a novel insertion sequence from Mycobacterium fortuitum using a trap vector based on inactivation of a lacZ reporter gene. Microbiology, 146, 1157. 31.R.Prasad, S.K. Lath, P.K., Mukerji, S.K., Agarwal, R. Srivastava,. 2001. Clinical utility of Polymerase chain reaction in patients of Pulmonary Tuberculosis. Ind. J. Tub. 48, 135. 32.R. Pathak, C. S. Pant, A. K. Shaw, A. P. Bhaduri, A. N. Gaikwad, S. Sinha, A. Srivastava, K. K. Srivastava, V. Chaturvedi, R. Srivastava, B. S. Srivastava. 2002. Baylis-Hillman Reaction: Convenient ascending syntheses and biological evaluation of Acyclic Deoxy monosaccharides as potential antimycobacterial agents. Biorg. Med. Chem. 10, 3187. 33.R. Pathak, A. K. Shaw, A. P. Bhaduri, K. V. G. Chandrasekhar, A. Srivastava, K. K. Srivastava, V. Chaturvedi, R. Srivastava, B. S. Srivastava, S. Arora, S. Sinha. 2002. Higher acyclic nitrogen containing deoxy sugar derivatives: a new lead in the generation of antimycobacterial chemotherapeutics. Biorg. Med. Chem. 10, 1695. 34.R.P. Tripathi, R. Tripathi, V.K. Tiwari, L. Bala, S. Sinha, S.A. Srivastava, R. Srivastava, B.S. Sivastava. 2002. Synthesis of glycosylated B-amino acids as new class of antitubercular agents. Eur. J. Med. Chem. 37, 773. 35.D.K. Deb, P. Dahiya, K.K. Srivastava, R. Srivastava. B.S. Srivastava. 2002. Selective identification of new therapeutic targets of Mycobacterium tuberculosis by IVIAT approach. Tuberculosis 82, 175.

36.D. Katiyar, V.K. Tiwari, R.P. Tripathi, A. Srivastava, V. Chaturvedi, R. Srivastava., B.S. Srivastava. 2003. Synthesis an antimycobacterial activity of 3,5-disubstituted thiadiazine thiones. Bioorg. Med. Chem. 11, 4369.

37.A.Mishra, A., R. Srivastava, C. Pruzzo, B.S. Srivastava. 2003. Mutation in tcpR gene (Vc0832) of Vibrio cholerae O1 causes loss of tolerance to high osmolarity and affects colonization and virulence in infant mice. J. Med. Microbiol. 52, 1.

38.P. Prem Raj, S. Srivastava, S. K. Jain, B. S. Srivastava, R. Srivastava.. 2003. Protection by live Mycobacterium habana cvaccine against Mycobacterium tuberculosis H37Rv challenge in mice. Indian J. Med. Res. 117, 139.

39.G. Panda, Shagufta , J. K. Mishra, V. Chaturvedi, A. K. Srivastava, R. Srivastava, B.S. Srivastava 2004. Diaryloxy methano phenanthrenes: a new class of antituberculosis agents. Bioorg. Med. Chem. 12 . 5269. 40.D. Katiyar, V.K. Tiwari, N. Tiwari, S.S. Verma, S. Sinha, A. Gaikwad, A. Srivastava, V., Chaturvedi, R. Srivastava, B.S. Srivastava and R.P. Tripathi . 2005. Synthesis of antimycobacterial activity of Glosylated Aminesand Amino Alcohols.. Eur. J. Med. Chem.40,(2005) 351.

41.M. Zampini, C. Pruzzo, V.P. Bondre, R. Tarsi, M. Cosmo, A. Bacciaglia, A. Chabbra, R. Srivastava, B.S. Srivastava.. 2005. Vibrio cholerae persistence in aquatic environments and colonization of intestinal cells: involvement of a common adhesion mechanism. FEMS Microbiol. Lett. 244 , 267.

42.R.P.S. Parti, S. Srivastava, R. Gachhui, K.K. Srivastava, R. Srivastava. 2005. Murine infection model for Mycobacterium fortuitum. Microbes and Infection. 7, 349.

43.R. Srivastava, D. Kumar, M.N. Waskar, M. Sharma, V.M. Katoch, B.S. Srivastava. 2006. Identification of a repetitive sequence belonging to a PPE gene of Mycobacterium tuberculosis and its use in diagnosis of tuberculosis . J. Med. Microbiol. 55, 1071.

44.R. K. Asthana,, A. Srivastava, A. P. Singh, Deepali, S. P. Singh, G.l Nath, R. Srivastava, B. S. Srivastava. 2006. Identification of an antimicrobial entity from the cyanobacterium Fischerella sp. isolated from bark of Azadirachta indica (Neem) tree . J. Applied Phycology 18 (1), 33.

45.P. Akhtar, S. Srivastava, A. Srivastava, M. Srivastava, B. S. Srivastava, R. Srivastava 2006. Rv3303c of Mycobacterium tuberculosis protects tubercle bacilli against oxidative stress in vivo and contributes to virulence in mice. Microbes and infection 8, 2855.

46.V. Srivastava, C. Rouanet, R. Srivastava, B. Ramalingam, C. Locht, B.S. Srivastava. 2007. Macrophage specific M. tuberculosis genes identified by green fluorescent protein and kanamycin resistance selection. Microbiology 153 (Pt 3) 659.

47.M. Saquib, M. K. Gupta, R. Sagar, Y. S. Prabhakar , A. K. Shaw, R. Kumar, P. R. Maulik, A. Gaikwad, S. Sinha, A. K. Srivastava, V. Chaturvedi, R. Srivastava, B.S. Srivastava.2007. C-3 Alkyl/Arylalkyl-2,3- dideoxy hex-2-enopyranosides as antitubercular agents: Synthesis, Biological Evaluation and QSAR study. J. Med. Chem., 50, 2942.

48. V. Srivastava, A. Jain, B.S. Srivastava, R. Srivastava. 2008. Selection of genes of Mycobacterium tuberculosis upregulated during residence in lungs of infected mice. Tuberculosis (Edinb). 88 (3) 171.

49.A. Saxena, V. Srivasrtava, R. Srivastava, B.S. Srivastava. 2008. Identification of genes of Mycobacterium tuberculosis upregulated during anaerobic persistence by fluorescence and kanamycin resistance selection. Tuberculosis (Edinb), 88 (6) 518. 50.R.P.S. Parti, R. Shrivastava, S. Srivastava, A.R. Subramanian, R. Roy, B.S. Srivastava, R. Srivastava. 2008. . A transposon insertion mutant of Mycobacterium fortuitum attenuated in virulence and persistence in a murine infection model that is complemented by Rv3291c of Mycobacterium tuberculosis. Microbial Pathogenesis. 45(5-6), 370.

51.A. Gupta, S. Bhakta, S. Kundu, M. Gupta, B.S. Srivastava, R. Srivastava. 2009. Fast-growing, non- infectious and intracellularly surviving drug-resistant Mycobacterium aurum: a model for high- throughput antituberculosis drug screening. J. Antimicrob. Chemotherapy 64(4), 774.

52.J. Kundu, R. Mazumdar, R. Srivastava, B.S. Srivastava. 2009. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae 01 challenge. Fems Immunol Med Microbiol. 56(2), 179.

53.R.K. Asthana, A. Deepali, M.K. Tripathi, A. Srivastava, A.P. Singh, S.P. Singh, G. Nath, R. Srivastava, B.S. Srivastava. 2009 . Isolation and identification of a new antibacterial entity from the Antarctic cyanobacterium Nostoc CCC 537. Journal of Applied Phycology 21(1), 81.

54.V. R. Reddy, P. Venkat Reddy, N. N. Mishra, P.K. Shukla, G. Yadav, R. Srivastava, A. K. Shaw. 2010. Synthesis and biological evaluation of glycal-derived novel tetrahydrofuran 1,2,3-triazoles by 'click' chemistry. Carbohydr Res. 345(11), 1515.

55.R. K. Gupta, B.S. Srivastava, R. Srivastava. 2010. Comparative expression analysis of rpf-like genes of Mycobacterium tuberculosis H37Rv under different physiological stress and growth conditions. Microbiology, 156 , 2714.

56. Haldar S, Bose M, Chakrabarti P, Daginawala HF, Harinath BC, Kashyap RS, Kulkarni S, Majumdar A, Prasad HK, Rodrigues C, Srivastava R, Taori GM, Varma-Basil M, Tyagi JS.. 2011. Improved laboratory diagnosis of tuberculosis - The Indian experience.Tuberculosis (Edinb). Julyl 15. PMID: 21764383

57. Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK, Dwivedi AK, Srivastava R, Srivastava BS. 2011. Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice.Vaccine. 2011;29(29-30):4754-60.

58. Saquib M, Husain I, Sharma S, Yadav G, Singh VK, Sharma SK, Shah P, Siddiqi MI, Kumar B, Lal J, Jain GK, Srivastava BS, Srivastava R, Shaw AK.2011. 2,3-dideoxy hex-2-enopyranosid-4-uloses as promising new anti-tubercular agents: design, synthesis, biological evaluation and SAR studies.Eur J Med Chem. 2011 46(6):2217-23.

59. Singh V, Chandra D, Srivastava BS, Srivastava R 2011. Biochemical and transcription analysis of acetohydroxyacid synthase isoforms in Mycobacterium tuberculosis identifies these enzymes as potential targets for drug development.Microbiology. ;157(Pt 1):29-37. 60. Singh V, Chandra D, Srivastava BS, Srivastava R 2011. Downregulation of Rv0189c, encoding a dihydroxyacid dehydratase, affects growth of Mycobacterium tuberculosis in vitro and in mice. Microbiology. ;157(Pt 1):38-46.

61. Sharma SK, Moe TS, Srivastava R, Chandra D, Srivastava BS. 2011. Functional characterization of VC1929 of Vibrio cholerae El Tor: role in mannose-sensitive haemagglutination, virulence and utilization of sialic acid. Microbiology.;157(Pt 11):3180-6.

62. Roy KK, Singh S, Sharma SK, Srivastava R, Chaturvedi V, Saxena AK. 2011. Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H₃₇Rv. Bioorg Med Chem Lett.;21(18):5589-93.

63. Kashyap VK, Gupta RK, Shrivastava R, Srivastava BS, Srivastava R, Parai MK, Singh P, Bera S, Panda G. 2012. In vivo activity of thiophene-containing trisubstituted methanes against acute and persistent infection of non-tubercular Mycobacterium fortuitum in a murine infection model. J Antimicrob

Chemother. ;67(5):1188-97.

Patents Granted

1. Mycobacterium tuberculosis specific DNA International fragment. Ranjana Srivastava, Deepak Kumar, B.S. Srivastava. US Patent no. 6,242,585 B1, 5. 6. 2001.

2. Mycobacterium tuberculosis specific DNA fragment. Ranjana Srivastava, Deepak Kumar, B.S. Srivastava. US Patent no. 6114514, 05. 09. 2000

3. Mycobacterium tuberculosis specific DNA fragment. Ranjana Srivastava, Deepak Kumar, B.S. Srivastava. European Patent EP0945462.; Germany, England, France and Netherland. 08/02/2006

4. Antitubercular extracts of Salicornia brachiata. M. R. Rathod, B. D. Shethia, J. B. Pandya, P. K. Ghosh, P.J. Dodia, Brahm S. Srivastava, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, M. Vairamani. U S patent 20070020351, 25.01. 2007.

5. Herbal extracts of Salicornia species, process of preparation thereof, use thereof against tuberculosis preparation thereof, use thereof against tuberculosis. M. R. Rathod, B. D. Shethia, J. B.Pandya, P. K. Ghosh, P. J. Dodia, Brahm S. Srivastava, Ranjana Srivastava, A. Srivastava, V. Chaturvedi US Patent 20070248704, . 25. 10. 2007.

National Patents Granted 1. A process for the production of bifunctional glucose and cellobiose inhibition resistant cellulase from a new microorganism Bacillus subtilis. R. Srivastava and B.S. Srivastava. Patent no 187232; 29.9.2002 2. A process for the production of bifunctional cellulase from Escherichia coli. R. Srivastava , K.K. Srivastava and B.S. Srivastava. Patent no. 187959; 3.7. 2003. 3. A process for the preparation of novel combinatorial library of 3-substituted amino-3-glycosylated propanoates useful as antifungal and antibacterial agents . R.P. Tripathi, B. Kundu, P. K. Shukla, S. Sinha, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava. Patent no. 194984; 17.03.2006 4. A novel combinatorial library of 3-substituted amino-3-glycosylated propanamides useful as antifungal and antibacterial agents. R. P. Tripathi, P. K. Shukla, S. Sinha, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava. Patent no. 196956; 23.06.2006. 5. A process for the preparation of novel combinatorial library of N1-glycosylated and N3- substituted ureas and thioureas useful as antitubercular agents . R. P. Tripathi, V. K. Tiwari, R. C. Mishra, Ranjana Srivastava, S. Sinha, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava. Patent no. 199556; 16.10.2006.

6. A process for the preparation of novel N1 , N n di glycosylated diaminoalcohol useful in chemotherapy of tubercular infections. R. P. Tripathi, V. K. Tiwari, N. Tewari, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K.K. Srivastava, S. Sinha, B. S. Srivastava, Patent no. 199829; 28.9.2007.

National Patents Filed

1. A process for the preparation of 1,3,5-thiazidin--2-thiones useful in chemotherapy of tubercular infections. R. P. Tripathi, D. Katiyar, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shanker Srivastava. 1098 DEL 2004; 6.11.2004. 2. Novel 1,3,5-thiazidine-2-thiones useful in chemotherapy of tubercular infections. R. P. Tripathi, D. Katiyar, Ranjana Srivastava, A. Srivastava, V. Chaturvedi, K. K. Srivastava, Brahm Shankar Srivastava 1100 DEL 2004; 6.11.2004. 3. A process for the synthesis of Novel Phenyl Cyclopropyl methanones useful as antitubercular agents. R. Grover, R.C. Mishra, S.S. Verma, R.P. Tripathi, Raja Roy, A.K. Dwivedi, S. Singh, R. Srivastava, A. Srivastava, V. Chaturvedi, Manju Y. Krishnan, B. S. Srivastava. 0636 DEL/ 2004; 31.3.2004 . 4. Herbal extracts of Salicornia species, process of preparation thereof, use thereof against tuberculosis. M.R. Rathod, B.S. Shetheia, J.B. Pandeya, P.K. Ghosh, P.J. Dodia, B.S. Srivastava, R. Srivastava, A. Srivastava, V. Chaturvedi. N 034/ NF/2003 4. Two assays to determine the activity of Isocitrate lyase from Mycobacterium tuberculosis and other mycobacteria . Manish Gupta, Ranjana Srivastava, Brahm S. Srivastava INF/PAT/09/2004 5. Mycobacterium tuberculosis specific DNA probes and a set of oligonucleotide primers for rapid diagnosis and to identify clinical isolates . Ranjana Srivastava, Deepak Kumar and Brahm S. Srivastava. 1760/DEL/04, 15.9.05 6. A Process for the preparation of novel 4-Nitrobutanoate Inhibitors of Isocitrate Lyase from Mycobacterium tuberculosis. Ranjana Srivastava, Brahm S. Srivastava M. K. Gupta, R. P. Tripathi, N. Tiwari, D. Katiyar, R. Ravishankar . 0671/DEL/2006; 07.12.2006. 7. C-3 aryl and alkyl substituted 2,3-dideoxyglucopyranoside as potential antitubercular agent. Ram sagar, M. Saquib, A.K. Shaw, A.N. Gaikwad, S.K. Sinha, A. Srivastava, V. Chaturvedi, M.Y. Krishnan, Ranjana Srivastava, B.S. Srivastava. 0533 DEL/2006; 23.02.2006

Sequences submitted in EMBL database

Two Mycobacterium fortuitum insertion sequences IS219 and IS220. Sequence submitted to EMBL Accession AJ 315500. 2002. These are new IS elements.

Technology Transferred

A new diagnostic reagent based on sequence specific M. tuberculosis DNA fragment: has been deveopled, licensed and commercialized as MycoView MTB PCR Detection Kit by Biotron Healthcare (I) Pvt. Ltd. India for early diagnosis of tuberculosis. The probe is a 1291 bp genomic DNA patented in USA, Europe and India.